英文名稱(chēng) | Pidilizumab (Anti-PDCD1 / PD-1 / CD279) |
---|---|
中文名稱(chēng) | 匹地利珠單抗 |
CAS號(hào) | 1036730-42-3 |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 |
---|---|---|---|---|
1 mg | 3-5days | ¥3600.00 | 登錄后可見(jiàn) | |
5 mg | 3-5days | ¥15500.00 | 登錄后可見(jiàn) | |
10 mg | 3-5days | ¥28500.00 | 登錄后可見(jiàn) | |
50 mg | 3-5days | ¥126000.00 | 登錄后可見(jiàn) | |
100 mg | 3-5days | ¥235000.00 | 登錄后可見(jiàn) |
英文名稱(chēng) | Pidilizumab (Anti-PDCD1 / PD-1 / CD279) |
---|---|
中文名稱(chēng) | 匹地利珠單抗 |
CAS號(hào) | 1036730-42-3 |
Pidilizumab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody targeting human PD-1 (programmed cell death 1; PDCD1). It has immunomodulating and antitumor activities and can be used in treatment of metastatic melanoma. MW :144.48 KD.